Eyal C. Attar
2022
In 2022, Eyal C. Attar earned a total compensation of $775.4K as Chief Medical Officer at Aprea Therapeutics, a 59% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $115,529 |
|---|---|
| Option Awards | $252,824 |
| Salary | $328,956 |
| Stock Awards | $78,078 |
| Total | $775,387 |
Attar received $329K in salary, accounting for 42% of the total pay in 2022.
Attar also received $115.5K in non-equity incentive plan, $252.8K in option awards and $78.1K in stock awards.
Rankings
In 2022, Eyal C. Attar's compensation ranked 3,572nd out of 5,760 executives tracked by ExecPay. In other words, Attar earned more than 38.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,572 out of 5,760 | 38th |
Division Manufacturing | 2,031 out of 3,136 | 35th |
Major group Chemicals And Allied Products | 973 out of 1,422 | 32nd |
Industry group Drugs | 910 out of 1,323 | 31st |
Industry Pharmaceutical Preparations | 663 out of 969 | 32nd |
Source: SEC filing on July 11, 2023.
Attar's colleagues
We found four more compensation records of executives who worked with Eyal C. Attar at Aprea Therapeutics in 2022.
News
Aprea Therapeutics CEO Christian Schade's 2022 pay falls 58% to $1.4M
July 11, 2023
Aprea Therapeutics CEO Christian Schade's 2021 pay slips 17% to $3.2M
June 10, 2022
Aprea Therapeutics CEO Christian Schade's 2020 pay rises 6% to $3.9M
April 28, 2021
Aprea Therapeutics CEO Christian Schade's 2019 pay jumps 520% to $3.7M
April 29, 2020